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Abstract
Background: Left ventricular hypertrophy (LVH) is common and associated with cardiovascular outcomes among
patients with known chronic kidney disease (CKD). However, the link between decreased estimated glomerular
filtration rate (eGFR) and left ventricular (LV) geometry remains poorly explored in general population. In this study,
we examined the gender-specific association between eGFR and LVH in the general population from rural
Northeast China.
Methods: This survey was conducted from July 2012 to August 2013. A total of 10907 participants (5,013 men and
5,894 women) from the rural Northeast China were randomly selected and examined. LV mass index (LVMI) was
used to define LVH (LVMI > 46.7 g/m2.7 in women; > 49.2 g/m2.7 in men). LV geometry was defined as normal, or
with concentric remodeling, eccentric or concentric hypertrophy, according to relative wall thickness (RWT) and
LVMI. Mildly decreased eGFR was defined as eGFR ≥ 60 and < 90 ml/min/1.73 m2, and moderate-severely decreased
eGFR was defined as eGFR < 60 ml/min/1.73 m2.
Results: As eGFR decreased, LVH showed a gradual increase in the entire study population. Multivariate analysis
revealed a gender-specific relationship between eGFR and LV geometry. Only in men, mildly decreased eGFR was
associated with concentric remodeling [odds ratio (OR): =1.58; 95% CI: 1.14–2.20; P < 0.01] and concentric LVH
OR = 1.63; 95% CI: 1.15–2.31; P < 0.01). And only in men, moderate-severely decreased eGFR was a risk factor for
concentric LVH (OR = 4.56; 95% CI: 2.14–9.73; P < 0.001) after adjusting for confounding factors.
Conclusions: These findings suggested that decreased eGFR was a risk factor for LV geometry in men, and a
gender-specific difference should be taken into account in clinical practice.
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Background
The dramatically increasing prevalence of chronic kidney
disease (CKD) is a great challenge to public health glo-
bally and also constitutes serious economic burden [1].
Reduced estimated glomerular filtration rate (eGFR), one
important marker of renal dysfunction, is a major risk
factor for cardiovascular disease (CVD) and has a signifi-
cant influence on the outcomes of the patients with CVD
[2]. Previous study has indicated that even a mild decrease
in eGFR could increase the risk of cardiovascular morbid-
ity and all-cause mortality [3]. Consensus is reached that
the relationship between renal and cardiac disease is close
and bidirection. Reduced eGFR is often associated volume
retention and increased preload, which could trigger sev-
eral biological signal cascades leading to cardiac hyper-
trophy [4]. On the other hand, preexisting cardiac disease
can accelerate renal damage and result in rapid deterior-
ation of eGFR [5].
Left ventricular hypertrophy (LVH), one type of cardiac
disease, emerges as an adaptive response to pressure or
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volume overload, appears to be a typical adverse cardiac
remodeling that occurs in CKD patients with decreased
eGFR [6]. Abnormal cardiac structure and function are in-
creased the risk of cardiovascular morbidity and mortality
[7]. Most studies pay much attention to LVH because it is
an independent risk factor of myocardial infarction, heart
failure, arrhythmia and other cardiovascular death [8, 9].
Various degree of decreased eGFR have significant ef-
fects on the development of LVH [3, 10–12], and the
available evidence showed that severely decreased eGFR
was strongly associated with increased left ventricular
mass (LVM) and increased prevalence of LVH [13]. Accu-
mulating evidence indicates that the prevalence of LVH is
inversely parallel to the value of eGFR [13, 14]. However,
few studies have investigated the effects of gender on the
correlation of eGFR and LVH. Furthermore, LVH could
be furthermore classified into concentric remodeling,
concentric hypertrophy, and eccentric hypertrophy based
on left ventricular mass index (LVMI) and relative wall
thickness (RWT) [15]. Data on reduced eGFR and LV
geometry are scarce.
We performed this study with the aims: 1) improving
LVH prevention by identifying its risk factors; 2) clarifying
whether prevalence of LVH is significantly correlated with
reduced eGFR; and 3) identifying gender-specific associ-
ation in a general population in rural Northeast China.
Methods
Approvals
The study was approved by the Ethics Committee of China
Medical University (Shenyang, China). All procedures were
performed under the relevant ethical standards. Written
consents were obtained from all participants after they had
been informed of the objectives, benefits, medical items
and confidentiality agreement regarding their personal in-
formation. For participants who were illiterate, we obtained
written informed consents from their proxies.
Study population
From January 2012 to August 2013, a representative
sample of individuals in rural areas of Liaoning Province
was recruited to present the prevalence, incidence and
natural history of cardiovascular risk factors in rural
areas of Liaoning Province. The study was a multi-stage,
stratified, random-cluster sampling scheme. Firstly, three
counties (Dawa, Zhangwu and Liaoyang County) were
randomly selected from rural areas of Liaoning province.
Then, one town was randomly selected from each three
counties. At last, a total of 26 rural villages from the
three towns were randomly selected. Participants with
pregnant or malignant tumors or mental disorders were
excluded from the study. A total of 14,016 residents
aged ≥ 35 years from each village were invited to partici-
pant the study and 11,956 participants (i.e. response rate
of 85.3%) agreed and completed the study. In this report,
we finally enrolled 10907 participants (5,013 men and
5,894 women) to examine the association between de-
creased eGFR and LV structural alterations in the Chinese
Northeast population.
Echocardiography measurements
The echocardiograms were obtained using a commercially
available Doppler echocardiograph (Vivid, GE Healthcare,
United States), with a 3.0-MHz transducer. The LV
dimension including end-diastolic LV internal diameter
(LVEDD), ventricular septal thickness (IVST) and poster-
ior LV wall thickness (PWT) were ascertained as guidance
with the recommendations of the American Society of
Echocardiography [16]. LVM was calculated according to
the formula: LVM (g) = 0.81 × (1.04 × [LVEDD+ IVST +
PWT]) 3 - (LVEDD) 3 + 0.06 [17]. LVH was defined as the
LVM/height2.7 > 46.7 g/m2.7 in women and > 49.2 g/m2.7
in men [18]. The relative wall thickness (RWT) = 2 ×
PWT/LVEDD at end-diastole and considered increased
if > 0.43 [15]. LV geometry was assessed from the LVM/
height2.7 combined with the RWT [15, 17]. Concentric
remodeling was defined by normal LVM/height2.7 and
increased RWT, eccentric hypertrophy by increased LVM/
height2.7 and normal RWT, and concentric LV hyper-
trophy by increased LVM/height2.7 and increased RWT.
Covariate measurements
Those participants who met with the inclusion criteria
completed a comprehensive questionnaire including ques-
tions about age, education, family income, physical activ-
ity, consumption of alcohol and cigarette in a face-to-face
interview. Before the survey was performed, we invited all
eligible investigators to attend an organized training ses-
sion and a strict test was evaluated to screen out qualified
investigators. During data collection, our inspectors would
support further instructions.
Blood pressure (BP) was measured with a standard-
ized automatic electronic sphygmomanometer (HEM-
907; Omron) in accordance with the British Hypertension
Society protocol [19]. The participants were advised to
avoid caffeinated beverages and exercise for at least
30 min before the measurement. During the measure-
ment, the participants were seated with their arms sup-
ported at the level of the heart and BP was taken three
times at 2-min intervals after at least 5 min of rest. The
mean of three BP measurements was calculated and
used in all analyses. The participants were informed of
wearing light-weight clothing and without shoes to ob-
tain anthropometric data on weight and height, which
were measured respectively to the nearest 0.1 kg and
0.1 cm. Body mass index (BMI) was calculated as the
weight in kilograms divided by the square root of the
height in meters.
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Fasting blood samples were collected in the morning
after at least 12 h of fasting for all participants. Blood
samples were obtained from an antecubital vein and
collected in vacutainer tubes containing EDTA. Blood
chemical analyses were performed at a central, certified
laboratory. Serum creatinine (SCr) was measured enzy-
matically on an autoanalyzer. GFR was estimated using
the equation originating from the CKD Epidemiology
Collaboration (CKD-EPI) equation [20], which is more
appropriate than the Modification of Diet in Renal Disease
(MDRD) Study group equation [21]. From this population,
we enrolled participants with normal eGFR defined as
eGFR ≥ 90 ml/min/1.73 m2. Mildly decreased eGFR was
defined as 60–90 ml/min/1.73 m2, and moderate-severely
decreased eGFR defined as eGFR < 60 ml/min/1.73 m2.
In addition, hemoglobin (Hb), fasting plasma glucose
(FPG), total cholesterol (TC), low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein choles-
terol (HDL-C), triglycerides (TG), and other routine
blood biochemical indexes were analyzed enzymatically
using an autoanalyzer. All laboratory equipments were
calibrated, and blinded duplicate samples were used for
these analyses.
Definitions
According to JNC-7 report [22], hypertension was de-
fined as systolic blood pressure (SBP) ≥ 140 mmHg
and/or diastolic blood pressure (DBP) ≥ 90 mmHg and/
or use of antihypertensive medications. Dyslipidemia was
defined according to the National Cholesterol Education
Program-Third Adult Treatment Panel (ATP III) criteria
[23]. Hyperuricemia was defined as serum uric acid > 375
umol/L in women and > 416 umol/L in men according to
guidelines [24].
Statistical analysis
Descriptive statistics were calculated for all the vari-
ables, including continuous variables (reported as mean
values and standard deviations) and categorical variables
(reported as numbers and percentages). Comparisons
were performed using t tests, χ2 tests, and one-way ANO-
VAs. Multivariate logistic regression analyses were used to
identify the association between eGFR and LV geometry in
men and women respectively, and odds ratios (ORs) and
corresponding 95% confidence intervals (CIs) were calcu-
lated. All the statistical analyses were performed using
SPSS version 22.0 software, and p values < 0.05 were con-
sidered to be statistically significant.
Results
Baseline clinical characteristics
The baseline characteristics of the 10,907 participants
with a mean age of 53.9 ± 10.5 years are summarized in
Table 1. The level of eGFR for men was higher
compared with women (93.97 ± 15.38 vs. 91.69 ± 16.26;
P < 0.001). Men had higher mean BP and lower TC than
women. The level of hemoglobin was significantly lower
in women than in men.
The mean value of IVST, LVEDD, PWT, LVM and LV
mass indexed for height2.7 in women were 0.85 ± 0.22,
4.55 ± 0.38, 0.84 ± 0.25 cm, 129.00 ± 87.48 g and 40.22 ±
27.49 g/h2.7, respectively, which were all significantly
lower than those in men.
Baseline characteristics of study population according to
eGFR
As shown in Table 2, participants with decreased eGFR
tended to be older and female. SBP, DBP, FPG, LDL-C,
TC, TG, and uric acid were significantly higher in
moderate-severely decreased eGFR group, but hemoglobin
and HDL-C showed the opposite trend. Additionally, sub-
jects with normal eGFR were more likely to be smokers
and drinkers. Moreover, participants with decreased eGFR
had a higher value of IVST, LVEDD, PWT, LVM and LV
mass indexed for height2.7.
Meanwhile, Fig. 1 showed that the prevalance of dif-
ferent cardiac remolding increased with the aggravation
of impaired kidney function, especially the concentric
hypertrophy.
Baseline characteristics of study population according to
LV geometry
Based on criteria listed in the methods, we divided the
study population into 4 groups according to LV geometry:
normal LV geometry (n = 8610; 78.94%), concentric remod-
eling (n = 485; 4.45%), eccentric hypertrophy (n = 1403;
12.86%), and concentric hypertrophy (n = 409; 3.74%). The
mean age of subjects with normal LV geometry were 52.5
± 10.1 years, which was significantly lower than that of
those who had either eccentric or concentric LVH. The
eGFR level gradually decreased in the four groups. Partici-
pants with concentric or eccentric hypertrophy had signifi-
cantly lower levels of HDL-C and significantly higher levels
of uric acid and FPG, SBP and DBP, compared to those
with normal LV geometry (Table 3).
Difference in the relationship between of eGFR and LVH
according to gender
Participants were categorized into three groups on the
basis of eGFR level. After adjusting for age, hyperten-
sion, hemoglobin, dyslipidemia, hyperuricemia, current
smoking and drinking, multivariate logistic regression
analysis revealed that the significant association between
mildly decreased eGFR and concentric remodeling
persisted (OR = 1.38; 95% CI: 1.11–1.72, P-value < 0.01,
Table 4). There was still a significant association be-
tween moderate-severely decreased eGFR and concentric
LVH (OR = 2.48; 95% CI: 1.50–4.08; P < 0.001, Table 4).
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Moreover, moderate-severely decreased eGFR was also
an independent risk factor for eccentric LVH in the whole
population (OR = 1.07; 95% CI: 0.74–1.53; P = 0.02,
Table 4).
In men, we found mildly decreased eGFR was signifi-
cantly associated with concentric remodeling (OR = 1.58;
95% CI: 1.14–2.20; P < 0.01, Table 4). However, the associ-
ation between decreased eGFR and eccentric LVH in men
did not achieve statistical significance after adjusting for
confounding factors mentioned above. In addition, both
mildly and moderate-severely decreased eGFR had various
degrees of impact on concentric LVH in men (OR = 1.63;
95% CI: 1.15–2.31; P < 0.01 vs OR = 4.56; 95% CI: 2.14–
9.73; P < 0.001, Table 4). Conversely in women, decreased
eGFR was not a significant risk factor for the different al-
teration of LV geometry.
Prediction of LV geometry according to eGFR
Figure 2 showed the AUCs (and 95% CIs) of eGFR in the
prediction of LV geometry. For concentric remolding, the
AUC was 0.64 (95% CIs: 0.60–0.67) for male and 0.60
(95% CIs: 0.57–0.63) for female. For eccentric LVH, the
AUC for was 0.61 (95% CIs: 0.60–0.64) for male and 0.60
(95% CIs: 00.58–0.63) for female. For concentric LVH, the
AUC was 0.65 (95% CIs: 0.610–0.69) for male and 0.66
(95% CIs: 0.62–0.70) for female.
Discussion
Echocardiographic studies in Caucasians, African Ameri-
cans and East Asians, indicate that a decline in renal
function is associated with LVH, particularly in patients
with both diabetes and hypertension [11, 25, 26]. How-
ever, few studies have reported on the association be-
tween decreased eGFR and LV geometry. The main
finding of our study was that different degrees of de-
creased eGFR were associated with different types of LV
geometry and gender-specific variations existed. In men
but not in women, mildly decreased eGFR was signifi-
cantly associated with concentric remodeling and con-
centric LVH, and moderate-severely decreased eGFR
was an independent risk factor for concentric LVH only
in men. These relationships were attenuated by adjusting
for confounding factors. To our knowledge, this is the
first study to report an association between decreased
eGFR and LV geometry in an Asian population and the
Table 1 Baseline characteristics of study population by gender
Variables All Men Women P-value
(N = 10907) (N = 5013) (N = 5894)
Age (years) 53.9 ± 10.5 54.4 ± 10.8 53.4 ± 10.3 <0.001
Smokers (%) 3833 2872 (57.3) 961 (16.3) <0.001
Drinkers (%) 2444 2278 (45.4) 166 (2.8) <0.001
SBP (mmHg) 141.55 ± 23.32 143.42 ± 22.49 139.96 ± 23.89 <0.001
DBP (mmHg) 81.98 ± 11.74 83.69 ± 11.78 80.52 ± 11.50 <0.001
TC (mmol/L) 5.24 ± 1.09 5.18 ± 1.04 5.30 ± 1.12 <0.001
TG (mmol/L) 1.63 ± 1.48 1.65 ± 1.63 1.62 ± 1.35 0.267
LDL-C (mmol/L) 2.93 ± 0.82 2.88 ± 0.79 2.97 ± 0.84 <0.001
HDL-C (mmol/L) 1.40 ± 0.38 1.40 ± 0.42 1.41 ± 0.34 0.675
Uric acid (mmol/L) 291.86 ± 85.08 334.41 ± 83.55 67.89 ± 0.88 <0.001
FPG (mmol/L) 5.91 ± 1.63 5.95 ± 1.65 5.87 ± 1.61 0.011
eGFR (ml/min/1.73 m2) 93.97 ± 15.38 93.97 ± 15.38 91.69 ± 16.26 <0.001
Hemoglobin (g/L) 138.64 ± 18.70 148.64 ± 18.18 130.13 ± 14.43 <0.001
ECG indices
IVST (cm) 0.88 ± 0.24 0.92 ± 0.27 0.85 ± 0.22 <0.001
LVEDD (cm) 4.71 ± 0.43 4.90 ± 0.41 4.55 ± 0.38 <0.001
PWT (cm) 0.87 ± 0.27 0.98 ± 0.28 0.84 ± 0.25 <0.001
RWT 0.37 ± 0.09 0.37 ± 0.09 0.37 ± 0.09 0.104
LVM (g) 143.11 ± 98.28 159.69 ± 107.28 129.00 ± 87.48 <0.001
LVM/H2.7 (g/h2.7) 40.79 ± 27.42 41.45 ± 27.31 40.22 ± 27.49 0.020
P values for comparisons were performed with t tests for continuous variables and χ2 test for categorical variables. SBP systolic blood pressure, DBP diastolic blood
pressure, TC triglyceride, TG total cholesterol, HDL-C high-density lipoprotein, LDL-C low-density lipoprotein, FPG fasting plasma glucose, eGFR estimated glomerular
filtration rate, ECG echocardiogram, IVST interventricular septum thickness, LVEDD left ventricular end-diastolic dimension, PWT posterior wall thickness, RWT
relative wall thickness
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first one to find a gender-specific difference in the rela-
tionship of decreased eGFR and LV geometry.
Consistent with previous studies [11, 13, 26], we found
that the prevalence of LVH generally increased in both
men and women as eGFR decreased. However, few stud-
ies have investigated the influence of eGFR on LV geom-
etry in the general population. Previous study based on
children aged 3–18 years found that substantial cardiac
remodeling of both concentric and eccentric type was
present at young age and early stages of chronic renal
insufficiency (GFR 49 ± 19 ml/min/1.73 m2) and preva-
lence of LVH was related to male gender [27]. We found
that an association between decreased eGFR and con-
centric LVH existed in a general population, which was
consistent with previous studies reporting the associ-
ation between CKD with concentric hypertrophy [28,
29]. Ernesto et al. reported that the risk of concentric
LVH was increased 2.96-fold in hypertensive patients
with an eGFR <30 ml/min/1.73 m2 compared to those
with an eGFR >60 ml/min/1.73 m2, whereas the associ-
ation of decreased eGFR and eccentric LVH was not
significant [30]. The observed increase in aortic stiffness
might explain the risk of concentric LV geometry in the
study participants with decreased eGFR. In both clinical
studies and animal models, aortic stiffness exposed the
left ventricle to increased afterload, which was linked
with concentric LVH [31, 32].
Differences in the association of renal dysfunction and
LV geometry in men and women have not been exten-
sively evaluated. In this population, decreased eGFR was
associated with concentric remolding and hypertrophy
only in men. Matteucci et al. reported that in children
with chronic renal insufficiency, the risk of LVH was
four-fold greater in boys than in girls [27] and Meisinger
et al. found that men with CKD had higher concentra-
tions of urinary albumin and greater cardiovascular risk
than women [33]. Concentric LVH is believed to result
primarily from hypertension and increased afterload
[34]. In the present study, men had significantly higher
values of BP and FPG, so it was quite possible for them
to have greater aortic stiffness and lower total arterial
compliance. Consequently, men might be more vulner-
able to the deleterious effects of early arterial load on
diastolic function and ventricular-arterial interaction,
which could be a reason for the gender-specific results.
In addition, the gender difference in the range of eGFR
Table 2 Baseline characteristics of study population by eGFR
Variables eGFR≥ 90 (ml/min/1.73 m2) 90 > eGFR≥ 60 (ml/min/1.73 m2) eGFR < 60 (ml/min/1.73 m2) P-value
N = 6578 N = 4098 N = 231
Age (years) 49.86 ± 8.67 60.00 ± 10.01 68.44 ± 9.48 <0.001
Male (%) 3289 (50.0) 1643 (40.1) 81 (35.1) <0.001
Smokers (%) 2490 (37.9) 1275 (33.3) 68 (29.4) <0.001
Drinkers (%) 1773 (27.0) 655 (16.0) 16 (0.7) <0.001
SBP (mmHg) 139.28 ± 22.47 144.34 ± 23.83 156.63 ± 26.72 <0.001
DBP (mmHg) 81.44 ± 11.54 82.67 ± 11.75 85.00 ± 15.51 <0.001
TC (mmol/L) 5.09 ± 1.03 5.45 ± 1.09 5.82 ± 1.65 <0.001
TG (mmol/L) 1.56 ± 1.55 1.73 ± 1.33 2.13 ± 1.73 <0.001
LDL-C (mmol/L) 2.85 ± 0.79 3.03 ± 0.83 3.27 ± 1.11 <0.001
HDL-C (mmol/L) 1.45 ± 0.40 1.35 ± 0.33 1.30 ± 0.37 <0.001
Uric acid (mmol/L) 297.37 ± 81.70 306.10 ± 82.35 394.83 ± 113.27 <0.001
FPG (mmol/L) 5.82 ± 1.65 6.01 ± 1.52 6.59 ± 2.42 <0.001
Hemoglobin (g/L) 140.03 ± 19.08 136.84 ± 17.80 130.98 ± 18.63 <0.001
ECG indices
IVST (cm) 0.87 ± 0.19 0.91 ± 0.31 0.97 ± 1.58 <0.001
LVEDD (cm) 4.72 ± 0.41 4.70 ± 0.44 4.77 ± 0.57 0.016
PWT (cm) 0.86 ± 0.24 0.88 ± 0.28 0.96 ± 0.49 <0.001
RWT 0.36 ± 0.11 0.38 ± 0.14 0.41 ± 0.21 <0.001
LVM (g) 143.00 ± 81.87 150.76 ± 119.51 172.48 ± 118.24 <0.001
LVM/H2.7 (g/h2.7) 39.26 ± 22.73 42.70 ± 33.33 50.36 ± 29.38 <0.001
P values for comparisons were performed with ANOVA for continuous variables and χ2 test for categorical variables. ANOVA analysis of variance, eGFR estimated
glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, TC triglyceride, TG total cholesterol, HDL-C high-density lipoprotein, LDL-C low-
density lipoprotein, FPG fasting plasma glucose, ECG echocardiogram, IVST interventricular septum thickness, LVEDD left ventricular end-diastolic dimension, PWT
posterior wall thickness, RWT relative wall thickness
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that promotes CVD might be explained in part by estro-
gen effects. Some studies found that estrogen had pro-
tective effects on cardiac structure. Li et al. reported that
the estrogen could resist adverse cardiac remodeling in a
rat transverse aortic constriction or sham surgery model
by inhibiting release of chymase [35]. Other studies also
confirmed that in a rat transverse aortic constriction or
sham surgery model [36].
The possible causes of LV geometry have been reviewed
recently, and although several studies point to the involve-
ment of age, anemia [37], inflammation [38], oxidative
stress [39] and disordered mineral metabolism [40], the
Fig. 1 Prevalance of abnormal LV geometry according to different eGFR and gender
Table 3 Baseline characteristics of study population by cardiac geometry
Variables Normal geometry Concentric remodeling Eccentric LVH Concentric LVH P-value
(N = 8610) (N = 485) (N = 1403) (N = 409)
Age (years) 52.5 ± 10.1 57.7 ± 11.1 59.0 ± 10.2 59.8 ± 10.6 <0.001
Male (%) 4590 (53.3) 268 (55.3) 827 (59.0) 209 (51.1) <0.001
Smokers (%) 3081 (35.8) 166 (34.2) 433 (30.9) 153 (37.4) 0.003
Drinkers (%) 1983 (23.0) 106 (21.9) 257 (18.3) 98 (24.0) 0.001
SBP (mmHg) 137.61 ± 20.75 147.56 ± 26.16 155.93 ± 25.23 167.97 ± 25.74 <0.001
DBP (mmHg) 80.66 ± 10.82 84.49 ± 12.89 86.26 ± 13.22 92.14 ± 14.32 <0.001
TC (mmol/L) 5.19 ± 1.06 5.40 ± 1.13 5.42 ± 1.20 5.63 ± 1.12 <0.001
TG (mmol/L) 1.57 ± 1.45 1.78 ± 1.57 1.87 ± 1.63 1.95 ± 1.34 <0.001
LDL-C (mmol/L) 2.89 ± 0.80 2.99 ± 0.84 3.06 ± 0.88 3.26 ± 0.95 <0.001
HDL-C (mmol/L) 1.41 ± 0.38 1.46 ± 0.47 1.35 ± 0.36 1.37 ± 0.37 <0.001
Uric acid (mmol/L) 287.89 ± 83.11 302.07 ± 92.25 302.70 ± 88.97 326.12 ± 91.74 <0.001
FPG (mmol/L) 5.84 ± 1.54 6.11 ± 1.79 6.17 ± 1.91 6.32 ± 1.97 <0.001
eGFR (ml/min/1.73 m2) 94.14 ± 15.49 88.11 ± 14.81 87.92 ± 16.03 85.19 ± 18.57 <0.001
Hemoglobin (g/L) 138.82 ± 19.26 138.64 ± 15.07 136.95 ± 16.23 140.64 ± 18.11 0.001
ECG indices
IVST (cm) 0.84 ± 0.08 0.97 ± 0.10 1.05 ± 0.56 1.15 ± 0.33 <0.001
LVEDD (cm) 4.67 ± 0.37 4.15 ± 0.35 5.14 ± 0.47 4.73 ± 0.39 <0.001
PWT (cm) 0.82 ± 0.07 0.96 ± 0.09 0.94 ± 0.09 1.39 ± 1.18 <0.001
RWT 0.36 ± 0.04 0.47 ± 0.04 0.39 ± 0.11 0.54 ± 0.30 <0.001
LVM (g) 128.69 ± 25.60 130.85 ± 30.95 199.53 ± 173.05 267.63 ± 330.52 <0.001
LVM/H2.7 (g/h2.7) 36.11 ± 5.98 37.56 ± 6.82 59.92 ± 45.78 77.52 ± 94.83 <0.001
P values for comparisons were performed with ANOVA for continuous variables and χ2 test for categorical variables. ANOVA analysis of variance, SBP systolic blood
pressure, DBP diastolic blood pressure, TC triglyceride, TG total cholesterol, HDL-C high-density lipoprotein, LDL-C low-density lipoprotein, FPG fasting plasma
glucose, eGFR estimated glomerular filtration rate, ECG echocardiogram, IVST interventricular septum thickness, LVEDD left ventricular end-diastolic dimension,
PWT posterior wall thickness, RWT relative wall thickness
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effects of those variables remain unclear. Gender-specific
difference in eGFR-associated LVH should be fully consid-
ered in studies of treatment and prevention strategies.
Limitations
There are some limitations of our study: (1) the present
study was a cross-sectional design, which restricted the
establishment of the cause and effect relationships.
Longitudinal studies are required to further confirm
these findings. (2) High BP should be established reliably
based on multiple measurements on 24-h ambulatory or
home recordings. Thus, the reproducibility might not be
ideal and there might be an overestimation of the preva-
lence in our study. (3) Due to the relative large sample
Table 4 Multivariate analysis of the relationship between CKD and LV geometry after adjusting for confounding factors
eGFR Concentric remodeling Eccentric LVH Concentric LVH
OR (95%CI) p value OR (95%CI) p value OR (95%CI) p value
Normal Reference Reference Reference
Mildly decreased 1.38 (1.11–1.72) <0.01 0.85 (0.74–0.97) 0.74 1.23 (0.96–1.57) 0.10
Moderate-severely decreased 1.47 (0.82–2.63) 0.20 1.07 (0.74–1.53) 0.02 2.48 (1.50–4.08) <0.001
Male
Normal Reference Reference Reference
Mildly decreased 1.58 (1.14–2.20) <0.01 0.95 (0.77–1.19) 0.67 1.63 (1.15–2.31) <0.01
Moderate-severely decreased 1.77 (0.68–4.60) 0.24 1.69 (0.93–3.07) 0.09 4.56 (2.14–9.73) <0.001
Women
Normal Reference Reference Reference
Mildly decreased 1.21 (0.91–1.62) 0.19 0.76 (0.63–0.91) <0.01 0.93 (0.66–1.30) 0.66
Moderate-severely decreased 1.29 (0.61–2.70) 0.50 0.70 (0.44–1.11) 0.13 1.40 (0.71–2.76) 0.33







































































































Fig. 2 The area under the receiver operating characteristic (ROC) curves of eGFR for the presence of LV geometry in both genders
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size, we have not analyzed microalbuminuria and only
used eGFR as criteria for classifying CKD. (4) Hormone
levels were not measured in our study, and the mechan-
ism could not be further studied.
Conclusion
In summary, mildly decreased eGFR was significantly as-
sociated with concentric remodeling and concentric
LVH, and moderate-severely decreased eGFR was an in-
dependent and significant risk factor for concentric LVH
in men. In rural areas of Northeast China, the impaired
eGFR and CVD are still major public health problems
and highly prevalent. The public and government should
pay more attention to renal function examination in
rural areas in China. Future analysis of the rural popula-
tion will clarify whether the incidence of LVH varies
with progression of renal dysfunction during further
follow-up.
Abbreviations
BP: Blood pressure; CI: Confidence interval; CKD: Chronic kidney disease;
CVD: Cardiovascular disease; DBP: Diastolic BP;
EDTA: Ethylenediaminetetraacetic acid; eGFR: Estimated glomerular filtration
rate; FPG: Fasting plasma glucose; HDL-C: High density lipoprotein-
cholesterol; IVST: End-diastolic interventricular septum thickness; LDL-C: Low
density lipoprotein-cholesterol; LVH: Left ventricular hypertrophy; LVM: Left
ventricular mass; LVMI: Left ventricular mass index; OR: Odds ratio; PWT: End-
diastolic posterior wall thickness; RWT: Myocardial relative wall thickness;




This study was supported by grants from the National Science and
Technology Support Program of China (No.2012BAJ18B08-7) and Liaoning
Research Center for Translational Medicine of Cardiovascular Disease (No.
2014225017).
Availability of data and material
The datasets generated and analyzed during the current study are not
publicly available because the project hasn’t been completed and the
follow-up study has been well underway. But they are available from the
corresponding author on reasonable request.
Authors’ contributions
All authors read and approved the final manuscript. YXS and XFG conceived
and carried out the study design, DXD, YC, YTC and SSY performed the
epidemiology survey and data input. DXD, YC and YTC analyzed the data.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written consents were obtained from all participants after they had been
informed of study’s objectives, benefits, medical procedures and confidentiality
safeguards for personal information. If the participants were illiterate, we
obtained written informed consents with the aid of their proxies.
Ethics approval and consent to participate
The study was approved by the Ethics Committee of China Medical University
(Shenyang, China). All procedures were performed in accordance with ethical
standards. Written consents were obtained from all participants after they had
been informed of the objectives, benefits, medical items and confidentiality
agreement regarding their personal information. For participants who were
illiterate, we obtained written informed consents from their proxies.
Received: 17 April 2016 Accepted: 23 December 2016
References
1. Tonelli M, Riellae M. Chronic kidney Disease and the Aging Population. Arab
J Nephrol Transplant. 2014;7(1):7–11.
2. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg
AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc
Nephrol. 2006;17(7):2034–47.
3. Edwards NC, Moody WE, Yuan M, Hayer MK, Ferro CJ, Townend JN, Steeds
RP. Diffuse interstitial fibrosis and myocardial dysfunction in early chronic
kidney disease. Am J Cardiol. 2015;115(9):1311–7.
4. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis,
detection, and prognosis. Circulation. 2000;102(4):470–9.
5. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, Salem D, Sarnak MJ,
Weiner DE. Cardiovascular disease and subsequent kidney disease. Arch
Intern Med. 2007;167(11):1130–6.
6. Lu J, Mu Y, Su Q, Shi L, Liu C, Zhao J, Chen L, Li Q, Yang T, Yan L, et al.
Reduced Kidney Function Is Associated With Cardiometabolic Risk Factors,
Prevalent and Predicted Risk of Cardiovascular Disease in Chinese Adults:
Results From the REACTION Study. J Am Heart Assoc. 2016;5:7.
7. Turakhia MP, Schiller NB, Whooley MA. Prognostic significance of increased
left ventricular mass index to mortality and sudden death in patients with
stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol.
2008;102(9):1131–5.
8. O’Neal WT, Almahmoud MF, Qureshi WT, Soliman EZ. Electrocardiographic
and Echocardiographic Left Ventricular Hypertrophy in the Prediction of
Stroke in the Elderly. J Stroke Cerebrovasc Dis. 2015;24(9):1991–7.
9. Ang DS, Fahey TP, Wright GA, Struthers AD. Development and validation of
a clinical score to identify echocardiographic left ventricular hypertrophy in
patients with cardiovascular disease. Am J Hypertens. 2008;21(9):1011–7.
10. Laddha M, Sachdeva V, Diggikar PM, Satpathy PK, Kakrani AL.
Echocardiographic assessment of cardiac dysfunction in patients of end stage
renal disease on haemodialysis. J Assoc Physicians India. 2014;62(1):28–32.
11. Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, Watanabe T,
Ohashi Y, Hishida A. Risk factors for increased left ventricular hypertrophy in
patients with chronic kidney disease. Clin Exp Nephrol. 2013;17(5):730–42.
12. Kiuchi MG, Graciano ML, De Queiroz Carreira MA, Kiuchi T, Chen S, Andrea BR,
Lugon JR. Effects of renal sympathetic denervation in left ventricular hypertrophy
in CKD refractory hypertensive patients. Int J Cardiol. 2016;202:121–3.
13. Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J,
He J, et al. Associations between kidney function and subclinical cardiac
abnormalities in CKD. J Am Soc Nephrol. 2012;23(10):1725–34.
14. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular
hypertrophy in the predialysis population: identifying opportunities for
intervention. Am J Kidney Dis. 1996;27(3):347–54.
15. Ganau A, Devereux RB, Roman MJ, De Simone G, Pickering TG, Saba PS,
Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and
geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;
19(7):1550–8.
16. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding
quantitation in M-mode echocardiography: results of a survey of
echocardiographic measurements. Circulation. 1978;58(6):1072–83.
17. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N.
Echocardiographic assessment of left ventricular hypertrophy: comparison
to necropsy findings. Am J Cardiol. 1986;57(6):450–8.
18. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, De Divitiis O,
Alderman MH. Left ventricular mass and body size in normotensive children
and adults: assessment of allometric relations and impact of overweight. J
Am Coll Cardiol. 1992;20(5):1251–60.
19. O’Brien E, Petrie J, Littler W, De Swiet M, Padfield PL, O’Malley K, Jamieson M,
Altman D, Bland M, Atkins N. The British Hypertension Society protocol for the
evaluation of automated and semi-automated blood pressure measuring devices
with special reference to ambulatory systems. J Hypertens. 1990;8(7):607–19.
20. Liu X, Wang Y, Wang C, Shi C, Cheng C, Chen J, Ma H, Lv L, Li L, Lou T. A
new equation to estimate glomerular filtration rate in Chinese elderly
population. PLoS ONE. 2013;8(11), e79675.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate
method to estimate glomerular filtration rate from serum creatinine: a new
prediction equation. Modification of Diet in Renal Disease Study Group. Ann
Intern Med. 1999;130(6):461–70.
Dai et al. BMC Cardiovascular Disorders  (2017) 17:24 Page 8 of 9
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones
DW, Materson BJ, Oparil S, Wright Jr JT, et al. The Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.
23. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A.
Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, And
Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
JAMA. 2001;285(19):2486–97.
24. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the
NHANES I epidemiologic follow-up study, 1971–1992. National Health and
Nutrition Examination Survey. JAMA. 2000;283(18):2404–10.
25. Bayauli MP, Lepira FB, Kayembe PK, M’Buyamba-Kabangu JR. Left ventricular
hypertrophy and geometry in type 2 diabetes patients with chronic kidney
disease. An echocardiographic study. Cardiovasc J Afr. 2012;23(2):73–7.
26. Matteucci MC, Chinali M, Rinelli G, Wuhl E, Zurowska A, Charbit M,
Pongiglione G, Schaefer F, Group ET. Change in cardiac geometry and
function in CKD children during strict BP control: a randomized study. Clin J
Am Soc Nephrol. 2013;8(2):203–10.
27. Matteucci MC, Wuhl E, Picca S, Mastrostefano A, Rinelli G, Romano C, Rizzoni
G, Mehls O, De Simone G, Schaefer F, et al. Left ventricular geometry in
children with mild to moderate chronic renal insufficiency. J Am Soc
Nephrol. 2006;17(1):218–26.
28. Iwashima Y, Horio T, Kamide K, Tokudome T, Yoshihara F, Nakamura S,
Ogihara T, Rakugi H, Kawano Y. Additive interaction of metabolic syndrome
and chronic kidney disease on cardiac hypertrophy, and risk of
cardiovascular disease in hypertension. Am J Hypertens. 2010;23(3):290–8.
29. Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in
new hemodialysis patients without symptomatic cardiac disease. Clin J Am
Soc Nephrol. 2010;5(5):805–13.
30. Paoletti E, De Nicola L, Gabbai FB, Chiodini P, Ravera M, Pieracci L, Marre S,
Cassottana P, Luca S, Vettoretti S, et al. Associations of Left Ventricular
Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD
and Hypertension. Clin J Am Soc Nephrol. 2016;11(2):271–9.
31. Hashimoto J, Westerhof BE, Westerhof N, Imai Y, O’Rourke MF. Different role
of wave reflection magnitude and timing on left ventricular mass reduction
during antihypertensive treatment. J Hypertens. 2008;26(5):1017–24.
32. Kobayashi S, Yano M, Kohno M, Obayashi M, Hisamatsu Y, Ryoke T, Ohkusa
T, Yamakawa K, Matsuzaki M. Influence of aortic impedance on the
development of pressure-overload left ventricular hypertrophy in rats.
Circulation. 1996;94(12):3362–8.
33. Meisinger C, Doring A, Lowel H, Group KS. Chronic kidney disease and risk
of incident myocardial infarction and all-cause and cardiovascular disease
mortality in middle-aged men and women from the general population.
Eur Heart J. 2006;27(10):1245–50.
34. Pieruzzi F, Antolini L, Salerno FR, Giussani M, Brambilla P, Galbiati S, Mastriani
S, Rebora P, Stella A, Valsecchi MG, et al. The role of blood pressure, body
weight and fat distribution on left ventricular mass, diastolic function and
cardiac geometry in children. J Hypertens. 2015;33(6):1182–92.
35. Li J, Jubair S, Janicki JS. Estrogen inhibits mast cell chymase release to
prevent pressure overload-induced adverse cardiac remodeling.
Hypertension. 2015;65(2):328–34.
36. Jia G, Aroor AR, Sowers JR. Estrogen and mitochondria function in
cardiorenal metabolic syndrome. Prog Mol Biol Transl Sci. 2014;127:229–49.
37. Tripepi G, Mattace-Raso F, Sijbrands E, Witteman J, Rapisarda F, Malatino L,
Mallamaci F, Zoccali C. Aging and left ventricular mass and function in
people with end-stage renal disease. J Am Geriatr Soc. 2011;59(9):1636–41.
38. Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, Cesari M,
Nourhashemi F. Proinflammatory cytokines, aging, and age-related diseases.
J Am Med Dir Assoc. 2013;14(12):877–82.
39. Dai DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP,
Prolla TA, Rabinovitch PS. Age-dependent cardiomyopathy in mitochondrial
mutator mice is attenuated by overexpression of catalase targeted to
mitochondria. Aging Cell. 2010;9(4):536–44.
40. Lopez-Aliaga I, Campos MS, Barrionuevo M, Coves F, Lisbona F. Influence of
dietary fat on nutritive utilization of protein in intestinally resected rats.
Nahrung. 1991;35(3):285–92.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dai et al. BMC Cardiovascular Disorders  (2017) 17:24 Page 9 of 9
